Thu, 31 Dec 2015 | BUSINESS SALE
Research Instruments, a company specialising in in-vitro fertilisation (IVF) developments, has been bought by US-based CooperSurgical.
Based in Falmouth, Cornwall, Research Instruments specialises in cutting-edge technology for both consumables and hardware used in IVF treatment and research.
CooperSurgical, the women's healthcare division of The Cooper Companies, Inc, eyed the UK business to help it strengthen its own IVF offering.
The business sale was agreed for the total cash consideration of $51 million and the British company received advice from a team at Ashfords, led by corporate partners Stuart Mathews and Andrew Betteridge.
Mr Matthews commented: “This sale is the culmination of years of hard work by William, Justin and David who together have built an outstanding global business.
“The deal brings together two important players in the IVF field and provides a strong strategic growth opportunity for CooperSurgical. We wish the business continued success under its new ownership.”
Research Instruments was founded by William Brown, Justin Retallack and David Lansdowne in the early 1980s and has expanded to become the largest global supplier of assisted reproductive technology.
View businesses for sale.
Beautifully presented restaurant in Cardiff. Affluent trading area. Run under management. Stunning premises, beautifully presented throughout. Offers invited.
Peak District/Stockport Postcode Area. Very well-established Private Family Dental Practice. Excellent high street location and with good transport links. Offers invited.
Prominent Town centre location. Imposing detached property. Newly refurbished in 2015. Customer seating for 110. High end fixtures and fittings. Offers invited.
28 Oddbins stores will remain open after the off-licence ret...
Tile retailer Topps Tiles has agreed the £18.1 million...
Sign up to receive our acquisition alert emails to get your FREE guide
Business Sale Report is your complete solution to finding great acquisition opportunities.
Join today to receive:
All this and much more, including the latest M&A news and exclusive resources